GlassScriptPhysician profile
Domingo C Barrientos
NPI 1184685281
$10,302.05
in general payments reported to CMS, 2019-2025
41 companies · $929 in 2025
The $929 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $2,143 · 2021: $2,256 · 2022: $1,737 · 2023: $1,600 · 2024: $1,218 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,704 · Gift: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.18 |
| Gift | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,681.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $987.26 | 2020-2025 | Vraylar, Linzess |
| Amgen INC. | $727.35 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $672.33 | 2020-2025 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $649.70 | 2019-2022 | |
| Amarin Pharma, INC. | $632.54 | 2019-2023 | |
| Glaxosmithkline, LLC. | $545.85 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $486.07 | 2019-2022 | |
| Allergan, INC. | $416.85 | 2019-2020 | |
| Astellas Pharma US INC | $333.01 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $299.43 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $236.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $230.94 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $220.81 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.45 | 2021-2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Domingo Barrientos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.